Treatment of Pneumocystis carinii with SCH 56592 In Vitro and In Vivo.

M. S. BARTLETT, D. LOEBENBERG, M. M. SHAW, P. J. DURANT, J. W. SMITH

Abstract: 

The new triazole SCH 56592 which is described as preventing ergosterol synthesis has been reported to be effective in the inhibition of Cryptococcus neoformans, Aspergillus spp., Candida spp., Blastomyces dermatitidis and Histoplasma capsulatum in both in vitro and in vivo studies. P. carinii is considered to be closely related to fungi although lipids of cell walls are primarily cholesterol rather than ergosterol. Itraconazole, ketoconazole and fluconazole were not active against P. carinii at concentrations tested in vitro or in vivo. SCH 56592 was tested in our short term culture model employing human embryonic lung fibroblast monolayers. The triazole was effective at 10 micro g/ml; it decreased the number of organisms to
1998

abstract No: 

NULL

Full conference title: 

38th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 38th